Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376159 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL3179881 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708630 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL708629 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL7287734 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL1448119 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL949983 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL26604823 | 1.00 | ABCB1 (0.52) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL13164545 | 0.95 | ABCB1 (0.47) | ABCB1AGTR2KLK7MCL1UCHL1 | |
| SCHEMBL29548192 | 0.93 | MCL1 (0.50) | ABCB1AGTR2KLK7MCL1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ASTRAZENECA AB (SE) | 2023-11-16 | — | — | US | disclosed |
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-9468693-B2 | Labeled molecular imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468693-B2 | Labeled molecular imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| EP-2931727-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | Abbvie Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015112333-A1 | LABELED MOLECULAR AGENTS FOR IMAGING CYSTINE/GLUTAMATE ANTI PORTER | GENERAL ELECTRIC COMPANY (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150202333-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150202333-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2015-07-23 | — | — | US | disclosed |
| WO-2014093337-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | ABBVIE, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| US-5756466-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365599-A1 | Arginase Inhibitors and Methods of Use Thereof | ARG1, ARG2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABCB1 870/4885AGTR2 119/4885KLK7 4255/4885 |
| US-20150202333-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | SLC7A11, GLS, SLC3A2 | ABCB1 823/4885AGTR2 1078/4885KLK7 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.